A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems

Published:November 26, 2021DOI:



      Our research group recently surveyed the clinical trial landscape in pancreatic adenocarcinoma and identified 430 active trials. These represent an opportunity to expand treatment options for patients with pancreatic adenocarcinoma. Our primary objective was to detail clinical trial participation among patients with pancreatic adenocarcinoma. Our secondary objective was to evaluate survival.


      We queried the National Cancer Database (2004–2016) for patients with pancreatic adenocarcinoma. Patients were stratified by trial participation: clinical trial or non-trial. Multivariable logistic regression was used to identify variables associated with trial participation. The Kaplan-Meier method and multivariable Cox hazards regression were used to analyze survival.


      In total, 261,483 patients were included: 1,110 (0.4%) were enrolled in a clinical trial. A total of 57 Black patients participated in a clinical trial (0.19% of Black patients). This was lower compared to White patients (n = 955, 0.49% of White patients, P < .001). After adjusting for demographic and clinical factors, Black patients were less likely to be enrolled in a clinical trial (odds ratio = 0.387, P < .001). Patients treated at nonacademic medical centers were less likely to be in a clinical trial.
      Trial participation was associated with an increased median survival relative to non-trial patients (stage IV: 9.0 vs 3.8 months, P < .001), and this association remained on multivariable regression (hazard ratio = 0.779, P < .001).


      Fewer than 1% of patients with pancreatic adenocarcinoma participated in a clinical trial. There are racial and sociodemographic disparities in clinical trial enrollment. An association was observed between clinical trial participants and prolonged survival.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • Jemal A.
        Cancer statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
      1. Howlander N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2017. National Cancer Institute., based on November 2019 SEER data submission, posted to the SEER web site April 2020. Accessed April 7, 2020.

        • Dovidio J.F.
        • Penner L.A.
        • Albrecht T.L.
        • Norton W.E.
        • Gaertner S.L.
        • Shelton J.N.
        Disparities and distrust: the implications of psychological processes for understanding racial disparities in health and health care.
        Soc Sci Med. 2008; 67: 478-486
        • Williams D.R.
        • Jackson P.B.
        Social sources of racial disparities in health.
        Health Affairs. 2005; 24: 325-334
        • Williams D.R.
        • Mohammed S.A.
        Discrimination and racial disparities in health: evidence and needed research.
        J Behav Med. 2009; 32: 20-47
        • Fiscella K.
        • Franks P.
        • Gold M.R.
        • Clancy C.M.
        Inequality in quality addressing socioeconomic, racial, and ethnic disparities in health care.
        JAMA. 2000; 283: 2579-2584
        • Regnante J.M.
        • Richie N.A.
        • Fashoyin-Aje L.
        • et al.
        US Cancer Centers of Excellence strategies for increased inclusion of racial and ethnic minorities in clinical trials.
        J Oncol Pract. 2019; 15: e289-e299
        • Zhang C.
        • Zhang C.
        • Wang Q.
        • Li Z.
        • Lin J.
        • Wang H.
        Differences in stage of cancer at diagnosis, treatment, and survival by race and ethnicity among leading cancer types.
        JAMA Netw Open. 2020; 3 (e202950–e202950)
        • Zeng C.
        • Wen W.
        • Morgans A.K.
        • Pao W.
        • Shu X.-O.
        • Zheng W.
        Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1990 to 2010.
        JAMA Oncol. 2015; 1: 88-96
        • Zavala V.A.
        • Bracci P.M.
        • Carethers J.M.
        • et al.
        Cancer health disparities in racial/ethnic minorities in the United States.
        Br J Cancer. 2021; 124: 315-332
        • Esnaola N.F.
        • Ford M.E.
        Racial differences and disparities in cancer care and outcomes: where’s the rub?.
        Surg Oncol Clin North Am. 2012; 21 (417–viii)
        • Freedman L.S.
        • Simon R.
        • Foulkes M.A.
        • et al.
        Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993: the perspective of NIH clinical trialists.
        Control Clin Trials. 1995; 16 (293–309): 277-279
        • Loree J.M.
        • Anand S.
        • Dasari A.
        • et al.
        Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018.
        JAMA Oncol. 2019; 5 (e191870–e191870)
        • Ford J.G.
        • Howerton M.W.
        • Lai G.Y.
        • et al.
        Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.
        Cancer. 2008; 112: 228-242
        • Murthy V.H.
        • Krumholz H.M.
        • Gross C.P.
        Participation in cancer clinical trials: race-, sex-, and age-based disparities.
        JAMA. 2004; 291: 2720-2726
        • Sateren W.B.
        • Trimble E.L.
        • Abrams J.
        • et al.
        How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.
        J Clin Oncol. 2002; 20: 2109-2117
        • Swanson G.M.
        • Bailar III, J.C.
        Selection and description of cancer clinical trials participants: science or happenstance?.
        Cancer. 2002; 95: 950-959
      2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1. 2020. Published online 2019. Available from: Accessed September 1, 2021.

        • Albain K.S.
        • Unger J.M.
        • Crowley J.J.
        • Coltman C.A.J.
        • Hershman D.L.
        Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
        J Nat Cancer Inst. 2009; 101: 984-992
        • Yothers G.
        • Sargent D.J.
        • Wolmark N.
        • et al.
        Outcomes among Black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
        J Nat Cancer Inst. 2011; 103: 1498-1506
        • Sparano J.A.
        • Wang M.
        • Zhao F.
        • et al.
        Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
        J Nat Cancer Inst. 2012; 104: 406-414
        • Vaziri-Gohar A.
        • Zarei M.
        • Brody J.R.
        • Winter J.M.
        Metabolic dependencies in pancreatic cancer.
        Front Oncol. 2018; 8: 617
      3. Matrisian LM, Berlin JD. The past, present, and future of pancreatic cancer clinical trials. American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology Annual Meeting. 2016;35:e205–215.

        • American College of Surgeons
        About the National Cancer Database.
      4. American College of Surgeons: The National Cancer Database 2016 PUF Data Dictionary.

        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.M.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45
        • Muller C.J.
        • MacLehose R.F.
        Estimating predicted probabilities from logistic regression: different methods correspond to different target populations.
        Int J Epidemiol. 2014; 43: 962-970
        • Hester C.A.
        • Kothari A.N.
        • Mason M.
        • et al.
        Surgical eligibility does not imply surgical equity. Ann Surg.
        (Published online 2021)
        Date accessed: November 20, 2021
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2016.
        CA Cancer J Clin. 2016; 66: 7-30
        • Katayama E.
        • Hue J.J.
        • Bajor D.L.
        • et al.
        A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?.
        Oncotarget. 2020; 11: 3489-3501
        • Hay M.
        • Thomas D.W.
        • Craighead J.L.
        • Economides C.
        • Rosenthal J.
        Clinical development success rates for investigational drugs.
        Nature Biotechnol. 2014; 32: 40-51
        • Wong C.H.
        • Siah K.W.
        • Lo A.W.
        Estimation of clinical trial success rates and related parameters.
        Biostatistics. 2019; 20: 273-286
        • DiMasi J.A.
        • Grabowski H.G.
        • Hansen R.W.
        Innovation in the pharmaceutical industry: new estimates of R&D costs.
        J Health Econ. 2016; 47: 20-33
        • Al-Refaie W.B.
        • Vickers S.M.
        • Zhong W.
        • Parsons H.
        • Rothenberger D.
        • Habermann E.B.
        Cancer trials versus the real world in the United States.
        Ann Surg. 2011; 254: 433-438
        • Conroy T.
        • Desseigne F.
        • Ychou M.
        • et al.
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. 2011; 364: 1817-1825
        • Conroy T.
        • Hammel P.
        • Hebbar M.
        • et al.
        FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.
        N Engl J Med. 2018; 379: 2395-2406
        • Neoptolemos J.P.
        • Palmer D.H.
        • Ghaneh P.
        • et al.
        Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
        Lancet. 2017; 389: 1011-1024
        • Colon-Otero G.
        • Smallridge R.C.
        • Solberg Jr., L.A.
        • et al.
        Disparities in participation in cancer clinical trials in the United States.
        Cancer. 2008; 112: 447-454
        • Fitzpatrick A.L.
        • Powe N.R.
        • Cooper L.S.
        • Ives D.G.
        • Robbins J.A.
        • Enright E.
        Barriers to health care access among the elderly and who perceives them.
        Am J Public Health. 2004; 94: 1788-1794
        • Onega T.
        • Duell E.J.
        • Shi X.
        • Wang D.
        • Demidenko E.
        • Goodman D.
        Geographic access to cancer care in the U.S.
        Cancer. 2008; 112: 909-918
      5. Nipp RD, Hong K, Paskett ED. Overcoming barriers to clinical trial enrollment. American Society of Clinical Oncology Educational Book. 2019;105–114.

      6. H.R.913 - Clinical Treatment Act. 116th Congress (2019–2020).
        • Pinto H.A.
        • McCaskill-Stevens W.
        • Wolfe P.
        • Marcus A.C.
        Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative.
        Ann Epidemiol. 2000; 10: S78-S84
        • Jimenez R.
        • Zhang B.
        • Joffe S.
        • et al.
        Clinical trial participation among ethnic/racial minority and majority patients with advanced cancer: what factors most influence enrollment?.
        J Palliat Med. 2013; 16: 256-262
        • Tejeda H.A.
        • Green S.B.
        • Trimble E.L.
        • et al.
        Representation of African-Americans, Hispanics, and Whites in National Cancer Institute cancer treatment trials.
        J Nat Cancer Inst. 1996; 88: 812-816
        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 2013; 369: 1691-1703
        • Jang R.W.
        • Caraiscos V.B.
        • Swami N.
        • et al.
        Simple prognostic model for patients with advanced cancer based on performance status.
        J Oncol Pract. 2014; 10: e335-e341
        • Kindler H.L.
        • Niedzwiecki D.
        • Hollis D.
        • et al.
        Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
        J Clin Oncol. 2010; 28: 3617-3622
      7. Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology Annual Meeting. 2016;35:185–198.

        • Hoehn R.S.
        • Rieser C.J.
        • Winters S.
        • et al.
        A Pancreatic cancer multidisciplinary clinic eliminates socioeconomic disparities in treatment and improves survival.
        Ann Surg Oncol. 2021; 28: 2438-2446
        • Chow C.J.
        • Habermann E.B.
        • Abraham A.
        • et al.
        Does enrollment in cancer trials improve survival?.
        J Am Coll Surg. 2013; 216: 774-781
        • Bilimoria K.Y.
        • Bentrem D.J.
        • Stewart A.K.
        • Winchester D.P.
        • Ko C.Y.
        Comparison of commission on cancer-approved and nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base.
        J Clin Oncol. 2009; 27: 4177-4181